Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial Letter uri icon


MeSH Major

  • Benzoates
  • Cardiomyopathies
  • Chelation Therapy
  • Iron Chelating Agents
  • Siderosis
  • Triazoles


  • The trial CICL670AUS04 was a single-arm, open-label study of the cardiac efficacy of 18 months of deferasirox monotherapy [1]. Cardiac response in this study was related to the degree of liver siderosis. Patients with mild to moderate liver siderosis improved their cardiac T2* while more severely siderotic patients did not, regardless of initial cardiac iron burden. In this letter, we report 2-year data in those patients who completed a 6-month extension phase (N 5 10). Cardiac and liver iron improved steadily during the 24-month period, with final cardiac T2* and LIC improving 37% and 27%, respectively, in this cohort. Serum ferritin and LVEF were not statistically different at anytime-point. When the extension phase (18-24 months) was considered in isolation, serum ferritin, liver iron concentration, and left ventricular ejection fraction were nearly identical to 18 month results. Despite this, cardiac T2* continued to trend higher, increasing 12.7% from 9.5 ms to 10.7 ms (P 5 0.06). Thus defersirox continued to demonstrate cardiac efficacy in patients with mild to moderate hepatic siderosis throughout 2 years of therapy.

publication date

  • October 2010



  • Letter


Digital Object Identifier (DOI)

  • 10.1002/ajh.21830

PubMed ID

  • 20799360

Additional Document Info

start page

  • 818

end page

  • 9


  • 85


  • 10